233 related articles for article (PubMed ID: 23855804)
21. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer.
Huang J; Baschnagel AM; Chen P; Gustafson G; Jaiyesmi I; Folbe M; Ye H; Akervall J; Krauss D
Int J Clin Oncol; 2014 Apr; 19(2):240-6. PubMed ID: 23479120
[TBL] [Abstract][Full Text] [Related]
22. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck.
Levy AR; Johnston KM; Sambrook J; Donato B; Penrod JR; Corral M; Chasen M
Curr Med Res Opin; 2011 Dec; 27(12):2253-9. PubMed ID: 22017232
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
[TBL] [Abstract][Full Text] [Related]
24. Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial.
Zenda S; Yamaguchi T; Yokota T; Miyaji T; Mashiko T; Tanaka M; Yonemura M; Takeno M; Okano T; Kawasaki T; Nakamori Y; Ishii S; Shimada S; Kanamaru M; Uchitomi Y
BMC Cancer; 2018 Sep; 18(1):873. PubMed ID: 30189840
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
Jensen AD; Krauss J; Potthoff K; Desta A; Habl G; Mavtratzas A; Windemuth-Kiesselbach C; Debus J; Münter MW
BMC Cancer; 2011 May; 11():182. PubMed ID: 21595970
[TBL] [Abstract][Full Text] [Related]
26. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
27. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
28. Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.
Cabezón-Gutiérrez L; Khosravi-Shahi P; Escobar-Álvarez Y
Oral Oncol; 2012 Apr; 48(4):293-7. PubMed ID: 22137799
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
Acevedo-Henao CM; Valette G; Miglierini P; Lefur E; Pradier O
Cancer Radiother; 2012 Oct; 16(7):601-3. PubMed ID: 23089070
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
Robert F; Ezekiel MP; Spencer SA; Meredith RF; Bonner JA; Khazaeli MB; Saleh MN; Carey D; LoBuglio AF; Wheeler RH; Cooper MR; Waksal HW
J Clin Oncol; 2001 Jul; 19(13):3234-43. PubMed ID: 11432891
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.
Merlano M; Russi E; Benasso M; Corvò R; Colantonio I; Vigna-Taglianti R; Vigo V; Bacigalupo A; Numico G; Crosetto N; Gasco M; Lo Nigro C; Vitiello R; Violante S; Garrone O
Ann Oncol; 2011 Mar; 22(3):712-717. PubMed ID: 20810547
[TBL] [Abstract][Full Text] [Related]
33. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
34. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab.
Koutcher LD; Wolden S; Lee N
Am J Clin Oncol; 2009 Oct; 32(5):472-6. PubMed ID: 19487913
[TBL] [Abstract][Full Text] [Related]
35. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
[TBL] [Abstract][Full Text] [Related]
36. Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab.
Murakami N; Yoshimoto S; Matsumoto F; Ueno T; Ito Y; Watanabe S; Kobayashi K; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Sumi M; Saito Y; Itami J
J Cancer Res Clin Oncol; 2015 Jan; 141(1):177-84. PubMed ID: 25119987
[TBL] [Abstract][Full Text] [Related]
37. The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck.
Adeberg S; Akbaba S; Lang K; Held T; Verma V; Nikoghosyan A; Bernhardt D; Münter M; Freier K; Plinkert P; Hauswald H; Herfarth K; Rieken S; Debus J; Jensen AD
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):167-173. PubMed ID: 31586664
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
40. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]